Parametric Portfolio Associates’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-180,436
| Closed | -$2.02M | – | 4004 |
|
|
2017
Q3 | $2.02M | Buy |
180,436
+70,197
| +64% | +$774K | ﹤0.01% | 2576 |
|
|
2017
Q2 | $1.21M | Buy |
110,239
+11,355
| +11% | +$114K | ﹤0.01% | 2863 |
|
|
2017
Q1 | $969K | Sell |
98,884
-8,728
| -8% | -$87.2K | ﹤0.01% | 2874 |
|
|
2016
Q4 | $1.16M | Buy |
107,612
+7,695
| +8% | +$76.9K | ﹤0.01% | 2743 |
|
|
2016
Q3 | $1.02M | Sell |
99,917
-24,351
| -20% | -$265K | ﹤0.01% | 2792 |
|
|
2016
Q2 | $1.62M | Sell |
124,268
-88,806
| -42% | -$1.16M | ﹤0.01% | 2481 |
|
|
2016
Q1 | $2.34M | Buy |
213,074
+112,215
| +111% | +$998K | ﹤0.01% | 2272 |
|
|
2015
Q4 | $928K | Sell |
100,859
-17,406
| -15% | -$146K | ﹤0.01% | 2840 |
|
|
2015
Q3 | $821K | Buy |
118,265
+7,011
| +6% | +$60K | ﹤0.01% | 2455 |
|
|
2015
Q2 | $1.09M | Sell |
111,254
-11,193
| -9% | -$102K | ﹤0.01% | 2737 |
|
|
2015
Q1 | $1.08M | Buy |
122,447
+15,004
| +14% | +$120K | ﹤0.01% | 2728 |
|
|
2014
Q4 | $941K | Buy |
107,443
+6,408
| +6% | +$51.9K | ﹤0.01% | 2830 |
|
|
2014
Q3 | $696K | Buy |
101,035
+59,635
| +144% | +$357K | ﹤0.01% | 2977 |
|
|
2014
Q2 | $218K | Buy |
41,400
+27,297
| +194% | +$133K | ﹤0.01% | 3688 |
|
|
2014
Q1 | $64K | Sell |
14,103
-27,450
| -66% | -$133K | ﹤0.01% | 3768 |
|
|
2013
Q4 | $209K | Sell |
41,553
-2,773
| -6% | -$13.3K | ﹤0.01% | 3605 |
|
|
2013
Q3 | $225K | Buy |
44,326
+7,183
| +19% | +$40K | ﹤0.01% | 3555 |
|
|
2013
Q2 | $184K | Buy |
+37,143
| New | +$177K | ﹤0.01% | 3488 |
|
Parametric Portfolio Associates's SCLN Position: Q4 2017 in Review
Parametric Portfolio Associates sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 180,436 shares — an estimated $2.02M sold.
Parametric Portfolio Associates first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $2.34M in Q1 2016. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Parametric Portfolio Associates reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Parametric Portfolio Associates sold 180,436 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $2.02M.
- Parametric Portfolio Associates first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Parametric Portfolio Associates's Sciclone Pharmaceuticals Inc position peaked at $2.34M in Q1 2016.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Parametric Portfolio Associates's 13F filing for Q4 2017, filed 14 Feb 2018.